Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Research and Markets: Oncology Pharmaceuticals Market in India 2014

RM, BIOGY

Research and Markets (http://www.researchandmarkets.com/research/2fjb2j/oncology) has announced the addition of the "Oncology Pharmaceuticals Market in India 2014" report to their offering.

Oncology Pharmaceutical Market in India 2014 highlights the analysis of the drivers and explains the factors for growth of the industry. Increasing number of cancer cases are the key drivers of this market. Lung, stomach, colon and breast cancer cause the maximum number of cancer deaths each year. Pharmaceutical companies are progressively increasing R&D expenditure on cancer vaccines.

The growing number of patients seeking treatment for cancer has made hospitals realize that cancer treatment is an important area for growth. Gleevec, Mabthera, Iressa, Avastin, Grafeel, Soliris and Herceptin are the top selling cancer drugs in the Indian market.

Alternative therapies such as cancer gene therapy and cancer cell therapy are increasingly becoming popular in cases where conventional therapies have failed. Combination therapies are being increasingly used in cancer treatments. Some challenges faced by the industry are the internal competition between large pharmaceutical companies. Another challenge is the penetration of Oncological drugs in rural areas which is very low. Various government initiatives have been undertaken to reduce the drug prices and various tax reforms and control programs are promoting the growth of the market as well. Manufacture of generic oncology drugs will help the pharmaceutical manufacturer gain a competitive advantage over others in a highly competitive pharma market. Companies should focus on development of new molecules in order to prolong the longevity of a blockbuster drug in the market.

Key Topics Covered:

  1. Executive Summary
  2. Macroeconomic Indicators
  3. Introduction
  4. Market Overview
  5. Export-Import
  6. Value Chain
  7. Drivers & Challenges
  8. Government Initiatives
  9. Regulations
  10. Competitive Landscape
  11. Recent Developments
  12. Strategic Recommendation
  13. Appendix

Companies Mentioned

Public Companies

  • Sanofi India Ltd.
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • GlaxoSmithKline Pharmaceuticals Ltd.
  • Novartis India Ltd.
  • Merck Ltd.
  • Pfizer Ltd.
  • Ranbaxy Laboratories Ltd.

Private Companies

  • Johnson and Johnson Ltd.
  • Roche Pharmaceuticals Pvt. Ltd.

For more information visit http://www.researchandmarkets.com/research/2fjb2j/oncology

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today